Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7054472 | 0.84 | CYP3A4 (0.36) | HTR2AHTR2CHTR2BTSHR | |
| SCHEMBL29560858 | 0.82 | TAAR1 (0.47) | HTR2AHTR2CHTR2BKMT2ATSHR | |
| SCHEMBL2843202 | 0.82 | TAAR1 (0.47) | HTR2AHTR2CHTR2BKMT2ATSHR | |
| SCHEMBL938227 | 0.82 | TAAR1 (0.47) | HTR2AHTR2CHTR2BKMT2ATSHR | |
| SCHEMBL29560461 | 0.82 | TAAR1 (0.47) | HTR2AHTR2CHTR2BKMT2ATSHR | |
| SCHEMBL4292448 | 0.82 | TAAR1 (0.47) | HTR2AHTR2CHTR2BKMT2ATSHR | |
| SCHEMBL13140491 | 0.79 | HTR2C (0.36) | HTR2AHTR2CHTR2BTSHRTAAR1 | |
| SCHEMBL7055337 | 0.79 | ALDH1A1 (0.42) | HTR2AHTR2CHTR2BTSHRTAAR1 | |
| SCHEMBL13264557 | 0.79 | OPRL1 (0.38) | HTR2CHTR2BTSHRTAAR1CYP2A13 | |
| SCHEMBL29178616 | 0.79 | HTR2A (0.44) | HTR2AHTR2CHTR2BMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407390-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA | 2019-09-10 | — | — | US | disclosed |
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2018-02-15 | — | — | US | disclosed |
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2018-02-15 | — | — | US | disclosed |
| US-9751836-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-05 | — | — | US | disclosed |
| US-9751836-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-05 | — | — | US | disclosed |
| EP-2678017-B1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-04-05 | — | — | EP | disclosed |
| US-8658797-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8658797-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-20120220629-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2012-08-30 | — | — | US | disclosed |
| WO-2012116176-A2 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2012-08-30 | — | — | WO | disclosed |
| US-20030124693-A1 | Enzymatic conversion of epoxides | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2003-07-03 | — | — | US | disclosed |
| EP-0611826-B1 | Processes for production of optically active epoxides | DAICEL CHEM (JP) | 2003-05-02 | — | — | EP | disclosed |
| EP-1287155-A1 | ENZYMATIC CONVERSION OF EPOXIDES | Rijksuniversiteit Groningen (NL) | 2003-03-05 | — | — | EP | disclosed |
| US-6515023-B2 | For inhibiting the aggregation of blood platelets; 3-(4-Aminomethyl-phenyl)-1-(2-(3,4-dichloro-phenyl)-2-hydroxy-ethyl)-1 -isopropyl-urea for example | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020007045-A1 | Thrombin receptor antagonists | MERCK & CO., INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001090397-A1 | ENZYMATIC CONVERSION OF EPOXIDES | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2001-11-29 | — | — | WO | disclosed |
| EP-1158054-A1 | Enzymatic conversion of epoxides | Rijksuniversiteit te Groningen (NL) | 2001-11-28 | — | — | EP | disclosed |
| US-6114582-A | DECYCLIZATION TO FORM A CHEMICAL INTERMEDIATE FOR PRODUCING AN ANTI-OBESITY AGENT AND ANTIDIABETIC AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-05 | — | — | US | disclosed |
| US-5672504-A | TREATING MIXED EPOXIDE ENANTIOMORPHS WITH MICROORGANISMS TO INCREASE CONCENTRATION OF OPTICALLY PURE S-ENANTIOMORPHS | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-30 | — | — | US | disclosed |
| EP-0611826-A2 | Processes for production of optically active epoxides | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007045-A1 | Thrombin receptor antagonists | F2R, TBXA2R, PTAFR | HTR2A 663/4885HTR2C 1280/4885HTR2B 499/4885 |
| US-20120220629-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | UTS2R, GPR119, GHSR | HTR2A 619/4885HTR2C 840/4885HTR2B 729/4885 |
| US-10407390-B2 | Asymmetric ureas and medical uses thereof | UTS2R, GPR119, GHSR | HTR2A 619/4885HTR2C 840/4885HTR2B 729/4885 |
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | UTS2R, GPR119, GHSR | HTR2A 619/4885HTR2C 840/4885HTR2B 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.